David L. Lucchino is the President and CEO of Frequency Therapeutics, a biotech company focused on developing treatments for hearing loss. He co-founded Korro Bio, Inc. and has a strong background in the biotech industry, where he has held leadership...

David L. Lucchino is the President and CEO of Frequency Therapeutics, a biotech company focused on developing treatments for hearing loss. He co-founded Korro Bio, Inc. and has a strong background in the biotech industry, where he has held leadership roles since 2014. Lucchino holds an MBA from MIT and degrees in Philosophy and Religious Studies, which provide a unique perspective on problem-solving. He has experience running businesses that have led to significant medical advancements, such as products that received FDA clearance. Recently, he faced health challenges, overcoming bacterial meningitis, demonstrating resilience. His compensation reflects his valuable contributions, including a 2023 total of around $2.5 million, part of which was from stock awards. Lucchino has been actively trading company stocks, with notable transactions in the millions recently, indicating strong belief in the company’s future. His involvement in industry groups, like MassBio, shows his commitment to advancing biotechnology on a larger scale.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Korro Bio, Inc. CEOs

K

David L. Lucchino

Founder and Ex-CEO of Korro Bio, Inc.

Education

MBA from MIT's Sloan School of Management, MS from Syracuse University, BA in Philosophy and Religious Studies from Denison University.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

CEO of Korro Bio, Inc. for

9 years 0 months (Nov 2014 - Nov 2023)

Previous Experience

Co-founder of Frequency Therapeutics, Inc. and held various leadership roles in biotechnology companies.

Rivals

Competitors/colleagues of David L. Lucchino

Holdings

See how much did David L. Lucchino make over time.

As CEO of Frequency Therapeutics, David L. Lucchino holds a significant stake in the company, with approximately 1.7 million shares of common stock, representing about 4.7% of total shares. His shareholding reflects his confidence in the company’s potential and innovative...

As CEO of Frequency Therapeutics, David L. Lucchino holds a significant stake in the company, with approximately 1.7 million shares of common stock, representing about 4.7% of total shares. His shareholding reflects his confidence in the company’s potential and innovative therapies. Recent insider trading shows fluctuations in his stock transactions, with notable sales amounting to over $1.5 million in November and December 2023 alone. In early 2024, his trades continued to demonstrate active involvement, with monthly sales ranging from $800K to $1.5 million. This trading activity suggests strategic financial management and belief in the future success of Frequency Therapeutics, particularly as the company moves forward with promising projects. There was a time when a significant portion of his wealth was tied to these holdings, reflecting both personal investment and professional commitment. It’s a story of a leader betting on his own company.

Total Stock Sold

$84.96K

KRRO

$84.96K

2,124 KRRO shares

What if they kept their stock?

If David L. Lucchino didn't sell their stock, today they would have:
Extra KRRO2,124 shares worth $32.88K.
This is -61.3% and $52.08K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of David L. Lucchino.

KRRO

$43.21K

KRRO at $37.38/share

Nov 22, 2023

Sale

KRRO

$41.26K

KRRO at $42.63/share

Nov 3, 2023

Sale

KRRO

6,000 shares

KRRO

Nov 3, 2023

Received

Compensation History

See how much did David L. Lucchino make over time.

David L. Lucchino's compensation reflects the responsibilities that come with leading a biotech company. In 2023, his total compensation was approximately $2.5 million, made up of a base salary of $558,767 and a significant portion from vested stock worth about $1.3 million. Notably, he did not receive a cash bonus this year, likely due to the company's restructuring and his temporary medical leave. In prior years, such as 2022, his earnings included stock options and other equity-based awards amid active business operations. The emphasis on stock awards shows that his success is tied to the company's performance, aligning his interests with shareholders. It highlights the pressures and expectations on biotech leaders—ensuring that scientific advancements translate into financial returns. His compensation emphasizes long-term goals even during challenging moments for the company.

Year

2023

Total Compensation

$3.88M

Salary

$558.77K

Board Justification

The compensation philosophy aims to align executive pay with company performance, ensuring competitive compensation to attract and retain top talent while motivating executives to achieve long-term success.

Bonus

$0.00

Board Justification

No bonus was awarded for the year 2023.

Other

$1.98M

Board Justification

This includes severance payments and other compensations related to the termination of employment due to the merger.

Restricted Stock

$1.34M(1.34M RSU)

Board Justification

The stock awards that vested in 2023 were granted as part of the executive compensation package, reflecting the company's performance and individual contributions during the year.

Performance Metrics

The performance metrics for determining compensation included individual performance and overall company performance metrics.

Other Korro Bio, Inc. CEOs

Here are other CEOs of Korro Bio, Inc.

Ram Aiyar, Ph.D., M.B.A.

Founder and CEO of Korro Bio, Inc.

November 2023 - Present